Centogene, a commercial-stage company focused on rare diseases, is opening a new laboratory in Hamburg, Germany—acquiring the former laboratory facilities and equipment of Provecs Medical GmbH, a company formerly active in cancer immunotherapy. The new laboratory, which is opening in April 2020, will enable increased testing capacity for the COVID-19 virus and will also result in the expansion of laboratory capacity for the company’s diagnostic testing of rare genetic diseases.
 
“The opening of our lab in Hamburg will significantly contribute to the scaling and success of our COVID-19 testing initiative,” said Arndt Rolfs, chief executive officer, Centogene. “Once we have overcome the challenges of this pandemic and returned to a sense of normalcy, we will further equip our labs in order to continue to strengthen our commitment to rare disease patients around the world—offering transformational medical solutions.”